| 1. |
López MJ, Carbajal J, Alfaro AL, et al. Characteristics of gastric cancer around the world. Crit Rev Oncol Hematol, 2023, 181(1): 103841. doi: 10.1016/j.critrevonc.2022.103841.
|
| 2. |
Norwood DA, Montalvan-Sanchez E, Dominguez RL, et al. Gastric cancer: emerging trends in prevention, diagnosis, and treatment. Gastroenterol Clin North Am, 2022, 51(3): 501-518.
|
| 3. |
Tan N, Wu H, Cao M, et al. Global, regional, and national burden of early-onset gastric cancer. Cancer Biol Med, 2024, 21(8): 667-678.
|
| 4. |
姚一菲, 孫可欣, 鄭榮壽. 《2022全球癌癥統計報告》解讀: 中國與全球對比. 中國普外基礎與臨床雜志, 2024, 31(7): 769-780.
|
| 5. |
Matsuoka T, Yashiro M. Novel biomarkers for early detection of gastric cancer. World J Gastroenterol, 2023, 29(17): 2515-2533.
|
| 6. |
Goto O, Kaise M, Iwakiri K. What’s new with endoscopic treatments for early gastric cancer in the “Post-ESD Era”?. Digestion, 2022, 103(1): 92-98.
|
| 7. |
Zeng Y, Yang J, Zhang JW. Early gastric cancer recurrence after endoscopic submucosal dissection: not to be ignored!. World J Gastrointest Oncol, 2024, 16(1): 8-12.
|
| 8. |
Ryu DG, Kim SJ, Choi CW, et al. Local Recurrence after endoscopic submucosal dissection of early gastric cancer. J Clin Med, 2023, 12(5): 2018. doi: 10.3390/jcm12052018.
|
| 9. |
李瑾, 朱付英, 徐婭, 等. miR-27b-3p聯合miR-215對早期胃癌內鏡黏膜下剝離術后復發的預測效能. 臨床外科雜志, 2024, 32(8): 830-834.
|
| 10. |
Shi MY, Mu YF, Shen N. Integrated analysis of miR-7-5p-related ceRNA network reveals potential biomarkers for the clinical outcome of gastric cancer. J Oncol, 2022, 2022: 8204818. doi: 10.1155/2022/8204818.
|
| 11. |
陳文妹, 毛葦, 孔燦燦, 等. 早期胃癌內鏡下胃黏膜剝離術完全切除后復發的風險模型構建. 局解手術學雜志, 2022, 31(3): 234-238.
|
| 12. |
中華醫學會腫瘤學分會, 中華醫學會雜志社. 中華醫學會胃癌臨床診療指南 (2021版). 中華醫學雜志, 2022, 102(16): 1169-1189.
|
| 13. |
Sun F, Huang Y, Sun Y, et al. Risk factors of additional surgery after non-curative endoscopic submucosal dissection for early gastric cancer. BMC Gastroenterol, 2023, 23(1): 383. doi: 10.1186/s12876-023-03006-9.
|
| 14. |
Hisada H, Sakaguchi Y, Oshio K, et al. Endoscopic treatment of superficial gastric cancer: present status and future. Curr Oncol, 2022, 29(7): 4678-4688.
|
| 15. |
Shaterabadi D, Zamani Sani M, Rahdan F, et al. MicroRNA biosensors in lung cancer. Clin Chim Acta, 2024, 552(1): 117676. doi: 10.1016/j.cca.2023.117676.
|
| 16. |
Hong SA, Lee S, Park J, et al. miR-199a and miR-199b facilitate diffuse gastric cancer progression by targeting Frizzled-6. Sci Rep, 2023, 13(1): 17480. doi: 10.1038/s41598-023-44716-0.
|
| 17. |
Yao YS, Shen HB, Zhou YJ, et al. MicroRNA-215 suppresses the proliferation, migration and invasion of non-small cell lung carcinoma cells through the downregulation of matrix metalloproteinase-16 expression. Exp Ther Med, 2018, 15(4): 3239-3246.
|
| 18. |
余芳, 趙晶晶, 李佳. FEN1、miR-215-5p在宮頸脫落細胞中的表達及其臨床診斷價值. 中國醫師雜志, 2022, 24(3): 428-431.
|
| 19. |
Zhang H, Lan X, Cai L, et al. miR-215-5p plays a key role in suppressing vascular invasion and recurrence in hepatocellular carcinoma by blocking vasculogenic mimicry. Front Biosci (Elite Ed), 2024, 16(1): 6. doi: 10.31083/j.fbe1601006.
|
| 20. |
李本杰, 周倩, 彭志紅. 早期胃癌中lncRNAFTX與miR-215表達及其與內鏡黏膜下剝離術預后的關系. 現代消化及介入診療, 2022, 27(1): 12-15,19.
|
| 21. |
郭雋馥, 李鄉南, 馬天馳, 等. miR-7-5p對人胃癌SGC-7901細胞干樣特性的影響. 中國組織工程研究, 2022, 26(19): 3030-3035.
|
| 22. |
李鹍鵬, 劉平賢, 杜新峰, 等. miR-7-5p在三陰性乳腺癌中的作用及其機制. 廣東醫學, 2022, 43(12): 1477-1484.
|
| 23. |
Liang Z, Liu L, Gao R, et al. Downregulation of exosomal miR-7-5p promotes breast cancer migration and invasion by targeting RYK and participating in the atypical WNT signalling pathway. Cell Mol Biol Lett, 2022, 27(1): 88. doi: 10.1186/s11658-022-00393-x.
|
| 24. |
劉瑞麗, 李蘭軍, 賈旻蕾, 等. 胃癌組織miR-7-5p、NOVA2表達與患者臨床預后的相關性. 檢驗醫學, 2023, 38(4): 325-329.
|
| 25. |
魏若愚, 黎春紅, 葉進軍. 胃癌ESD術后CA724、NLR、MLR、PLR水平與術后復發的關系. 海南醫學, 2022, 33(18): 2337-2339.
|